Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis.

Suppr

超能文献

作者信息

Straumann Alex, Bussmann Christian, Conus Sébastien, Beglinger Christoph, Simon Hans-Uwe

出版信息

J Allergy Clin Immunol. 2008 Aug;122(2):425-7. doi: 10.1016/j.jaci.2008.06.012.

DOI:10.1016/j.jaci.2008.06.012

PMID:18678345

Abstract

摘要

相似文献

Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis.

J Allergy Clin Immunol. 2008 Aug;122(2):425-7. doi: 10.1016/j.jaci.2008.06.012.

Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

J Allergy Clin Immunol. 2006 Dec;118(6):1312-9. doi: 10.1016/j.jaci.2006.09.007. Epub 2006 Nov 7.

Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.

Br J Haematol. 2002 Feb;116(2):334-7.

Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.

J Allergy Clin Immunol. 2010 Jul;126(1):175-7. doi: 10.1016/j.jaci.2010.04.029. Epub 2010 Jun 12.

Efficacy and safety of infliximab in active SLE: a pilot study.

Lupus. 2009 Jul;18(8):690-7. doi: 10.1177/0961203309102557.

TNF-α antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial.

J Clin Psychopharmacol. 2010 Jun;30(3):343-5. doi: 10.1097/JCP.0b013e3181dcf0de.

Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo.

Med Hypotheses. 2009 May;72(5):546-7. doi: 10.1016/j.mehy.2008.12.033. Epub 2009 Feb 6.

Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab.

Eur J Clin Invest. 2004 Sep;34(9):641-2. doi: 10.1111/j.1365-2362.2004.01390.x.

Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.

Rheumatology (Oxford). 2009 Aug;48(8):1012-3. doi: 10.1093/rheumatology/kep126. Epub 2009 May 22.

Infliximab and the TNF-alpha system.

Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G612-20. doi: 10.1152/ajpgi.90576.2008. Epub 2009 Jan 8.

引用本文的文献

Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review.

Pharmaceutics. 2025 Jun 7;17(6):753. doi: 10.3390/pharmaceutics17060753.

Eosinophilic Esophagitis Pathogenesis: All Clear?

Inflamm Intest Dis. 2025 May 8;10(1):135-150. doi: 10.1159/000546241. eCollection 2025 Jan-Dec.

From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis.

Gastroenterol Hepatol (N Y). 2025 May;21(5):298-303.

Off-Label Use of Monoclonal Antibodies for Eosinophilic Esophagitis in Humans: A Scoping Review.

Biomedicines. 2024 Nov 11;12(11):2576. doi: 10.3390/biomedicines12112576.

Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.

Inflamm Intest Dis. 2024 Jul 26;9(1):199-209. doi: 10.1159/000540275. eCollection 2024 Jan-Dec.

From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis.

Biomolecules. 2024 Aug 28;14(9):1080. doi: 10.3390/biom14091080.

Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review.

J Clin Med. 2024 Jul 14;13(14):4119. doi: 10.3390/jcm13144119.

Eosinophilic esophagitis: Current concepts in diagnosis and management.

Saudi J Gastroenterol. 2024 Jul 1;30(4):210-227. doi: 10.4103/sjg.sjg_50_24. Epub 2024 May 16.

Successful Treatment of Eosinophilic Enterocolitis in an Adult Patient With Adalimumab.

ACG Case Rep J. 2024 Feb 21;11(2):e01285. doi: 10.14309/crj.0000000000001285. eCollection 2024 Feb.

The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs.

Int J Mol Sci. 2024 Jan 30;25(3):1702. doi: 10.3390/ijms25031702.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验